Thamotharampillai Dileepan

Title: Thamotharampillai Dileepan: Innovator in Major Histocompatibility Class II Molecules

Introduction

Thamotharampillai Dileepan is a notable inventor based in Minneapolis, MN (US). He has made significant contributions to the field of immunology through his innovative work on major histocompatibility class II (MHCII) molecules. His research focuses on enhancing the affinity of these molecules for CD4 co-receptors, which is crucial for T cell activation and phenotyping.

Latest Patents

Dileepan holds a patent for "Co-receptor affinity enhanced major histocompatibility class II molecules." This patent describes variant MHCII beta chains, as well as heterodimers and multimers that include MHCII alpha chains and the variant MHCII beta chains. The disclosed heterodimers and multimers exhibit a higher affinity for CD4 co-receptors compared to wild type MHCII beta chains. This advancement is advantageous for methods involving the phenotyping or activation of CD4 T cells.

Career Highlights

Thamotharampillai Dileepan is affiliated with the University of Minnesota, where he continues to engage in groundbreaking research. His work has implications for improving immune responses and developing therapeutic strategies in immunology.

Collaborations

Dileepan collaborates with esteemed colleagues, including Marc Kevin Jenkins and Deepali Malhotra. Their combined expertise contributes to the advancement of research in the field of immunology.

Conclusion

Thamotharampillai Dileepan is a prominent inventor whose work on MHCII molecules has the potential to significantly impact immunological research and therapies. His innovative contributions continue to pave the way for advancements in the understanding of immune responses.